Interim results to 30 June 2024.

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI’s journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement and compliance with the US FDA Lab Developed Test ruling.

Paul Pagano and David Anderson give a presentation on LungLife's results for the year ended 31 December 2023, via the Investor Meet Company platform.

Paul Pagano and David Anderson give a presentation on LungLife's Interim results for the six months ended 30 June 2023, via the Investor Meet Company platform.

In this interview, Paul Pagano CEO of Lunglife AI #LLAI takes Vox through today’s ‘in line’ H1’23 results and the next steps wrt commercialising its ground-breaking early stage lung cancer blood test.

Paul Pagano and David Anderson give a presentation on LungLife's Interim results for the six months ended 30 June 2022, via the Investor Meet Company platform.

Paul Pagano and David Anderson give a presentation on LungLife's Annual Results for the year ended 31 December 2021, via the Investor Meet Company platform.

LungLife AI: Edison Open House Healthcare 2022

Paul Pagano and David Anderson talk with Justin Waite of VOX Markets.

Paul Pagano and David Anderson's presentation to the investor community on the results to the period.